Chapter 420: The Metabolic Syndrome¶
Chapter 420 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Metabolic syndrome is defined by central obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and hyperglycemia (NCEP/ATPIII criteria).
- Insulin resistance is the central pathophysiological mechanism, driven by excess free fatty acids, adipokine dysregulation, and inflammation.
- Lifestyle modification (diet, exercise) is foundational; pharmacologic agents (statins, GLP-1 agonists) and bariatric surgery are key for severe cases.
- Global prevalence is ~35% in U.S. adults, rising with age and obesity; children show 12-30% prevalence in obese/overweight groups.
- Management prioritizes reducing cardiovascular risk through lipid control, blood pressure management, and addressing insulin resistance.
1. DEFINITION & OVERVIEW¶
Metabolic syndrome is a cluster of metabolic abnormalities (central obesity, hypertriglyceridemia, low HDL, hypertension, hyperglycemia) that increase CVD and diabetes risk. Criteria include NCEP/ATPIII and harmonizing definitions (Table 420-1).
Table 420-1: NCEP/ATPIII 2001 and Harmonizing Definition Criteria¶
| Criteria | NCEP:ATPIII 2001 | Harmonizing Definition |
|---|---|---|
| Central Obesity | Waist circumference >102 cm (men), >88 cm (women) | Waist circumference (cm): ‡94 (men), ‡80 (women) |
| Hypertriglyceridemia | Triglycerides ‡150 mg/dL or medication | Fasting triglycerides >150 mg/dL or medication |
| Low HDL | HDL <40 mg/dL (men), <50 mg/dL (women) | HDL <40 mg/dL (men), <50 mg/dL (women) |
| Hypertension | BP ‡130/85 mmHg or medication | BP >130 mmHg systolic or >85 mmHg diastolic or medication |
| Hyperglycemia | Fasting glucose ‡100 mg/dL or medication | Fasting glucose ‡100 mg/dL (alternative: drug treatment for elevated glucose) |
1.1 Diagnostic Criteria¶
Three or more of: central obesity (waist circumference >102 cm/men, >88 cm/women), hypertriglyceridemia (>150 mg/dL), low HDL (<40 mg/dL/men, <50 mg/dL/women), hypertension (>130/85 mmHg), or fasting glucose ≥ 100 mg/dL.
1.2 Clinical Significance¶
Strongly associated with CVD risk (2x higher mortality), type 2 diabetes (3-5x risk), and complications like NASH, CKD, and obstructive sleep apnea.
2. EPIDEMIOLOGY¶
Global prevalence varies by age, ethnicity, and geography. U.S. adults: ~35% meet NCEP criteria. Prevalence increases with age (48.6% ≥ 60 years). Obesity epidemic drives rising rates, especially in children (12-30% in obese/overweight groups).
2.1 Demographics¶
Higher in older adults, non-Hispanic whites, and populations with central obesity. Asian populations show higher prevalence due to visceral fat distribution.
2.2 Global Trends¶
Industrialization and aging populations correlate with rising obesity and metabolic syndrome. NHANES data shows 33.4% prevalence in U.S. adults (1999–2018).
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Insulin resistance is central, driven by free fatty acids, adipokine dysregulation, and inflammation. Genetic factors, gut microbiome, and mitochondrial dysfunction contribute. Visceral adiposity exacerbates insulin resistance and systemic inflammation.
3.1 Insulin Resistance Mechanisms¶
Excess free fatty acids impair insulin signaling, reduce glucose uptake, and promote hepatic gluconeogenesis. Adipokines (leptin, adiponectin) and cytokines (IL-6, TNF- α ) mediate inflammation and insulin resistance.
3.2 Role of Adipose Tissue¶
Visceral fat releases free fatty acids and proinflammatory cytokines. Adipose-derived factors (e.g., resistin, visfatin) contribute to systemic inflammation and metabolic derangements.
4. CLINICAL FEATURES¶
Asymptomatic in early stages. Physical findings: central obesity, hypertension, acanthosis nigricans. Associated with CVD, type 2 diabetes, NASH, and obstructive sleep apnea. Increased risk of stroke, peripheral vascular disease, and Alzheimer’s.
4.1 Associated Diseases¶
Cardiovascular disease (2x higher mortality), type 2 diabetes (3-5x risk), nonalcoholic fatty liver disease (NAFLD), and metabolic-associated steatohepatitis (MASH).
4.2 Complications¶
Increased risk of myocardial infarction, stroke, CKD, and mortality. Obesity-related comorbidities (e.g., polycystic ovary syndrome, sleep apnea) exacerbate metabolic risk.
5. DIFFERENTIAL DIAGNOSIS¶
Hyperthyroidism, Cushing’s syndrome, PCOS, obstructive sleep apnea, and chronic kidney disease. Distinguish from isolated obesity or diabetes without metabolic clustering.
5.1 Mimicking Conditions¶
Hyperthyroidism (elevated T3/T4), Cushing’s (central obesity, hypertension), PCOS (hirsutism, anovulation), and sleep apnea (daytime sleepiness, snoring).
6. INVESTIGATIONS & DIAGNOSIS¶
Clinical assessment (waist circumference, BP) and lab tests: fasting glucose, lipid panel, hsCRP, uric acid, and liver enzymes. Use of MAFLD fibrosis score or elastography for NAFLD assessment.
6.1 Diagnostic Tools¶
Waist circumference measurement, fasting lipid profile, HbA1c, and renal function tests. Sleep study for suspected obstructive sleep apnea.
6.2 Biomarkers¶
hsCRP (inflammation), adiponectin (insulin sensitivity), and urinary albumin/creatinine ratio (endothelial dysfunction).
7. MANAGEMENT & TREATMENT¶
Lifestyle modification (diet, exercise) is first-line. Pharmacologic agents include statins, GLP-1 agonists, fibrates, and bariatric surgery for severe obesity. Target LDL-C <100 mg/dL in high-risk patients.
7.1 Lifestyle Interventions¶
Caloric restriction (500 kcal/day), 150 min/week moderate exercise, and behavior modification. Weight loss of 5-10% reduces metabolic risk.
7.2 Pharmacologic Agents¶
Statins (first-line), GLP-1 agonists (semaglutide, tirzepatide), fibrates (fenofibrate), and ezetimibe. PCSK9 inhibitors for refractory hypercholesterolemia.
7.3 Surgical Options¶
Bariatric surgery (gastric bypass, sleeve gastrectomy) for BMI >40 or >35 with comorbidities. Reduces metabolic syndrome components and improves diabetes.
8. PROGNOSIS & COMPLICATIONS¶
Increased risk of CVD mortality (1.34x), type 2 diabetes, and end-stage liver disease. Complications include NASH, CKD, and metabolic-associated fatty liver disease (MAFLD).
8.1 Cardiovascular Risk¶
2x higher risk of CVD mortality. Patients with metabolic syndrome and diabetes have 3x higher risk of myocardial infarction.
8.2 Long-Term Outcomes¶
Weight regain common after weight loss. Proactive management reduces ASCVD events and mortality.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Metformin may be used for gestational diabetes. Pediatrics: Focus on lifestyle modification. Elderly: Monitor for drug interactions and frailty. Ethnic disparities in visceral fat distribution affect risk profiles.
9.1 Pregnancy¶
Avoid thiazolidinediones (TZDs) due to fetal risks. Metformin may be used for gestational diabetes and PCOS.
9.2 Ethnic Variations¶
Asian populations show higher visceral fat accumulation despite similar BMI, increasing metabolic syndrome risk.
10. KEY POINTS & CLINICAL PEARLS¶
- Insulin resistance is the core pathophysiology. 2. Lifestyle modification is foundational. 3. Statins and GLP-1 agonists are first-line pharmacologic agents. 4. Bariatric surgery improves metabolic syndrome and diabetes. 5. Monitor for CVD and liver complications (e.g., NASH).